Recent advances in the development of subunit-based RSV vaccines

Palivizumab epitope–displaying virus-like particles protect rodents from RSV challenge

(2015) Jeanne H. Schickli et al.   JOURNAL OF CLINICAL INVESTIGATION

RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets

(2015) Cory J. Knudson et al.   PLoS Pathogens

A Novel Respiratory Syncytial Virus (RSV) F Subunit Vaccine Adjuvanted with GLA-SE Elicits Robust Protective TH1-Type Humoral and Cellular Immunity In Rodent Models

(2015) Stacie L. Lambert et al.   PLoS One

Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity

(2014) R. Garg et al.   JOURNAL OF GENERAL VIROLOGY

Effect of epitope-CpG-DNA-liposome complex without carriers on vaccination of respiratory syncytial virus infection

(2014) Byoung Kwon Park et al.   Journal of the Korean Society for Applied Biological Chemistry

Inhibition of the Human Respiratory Syncytial Virus Small Hydrophobic Protein and Structural Variations in a Bicelle Environment

(2014) Y. Li et al.   JOURNAL OF VIROLOGY

Recent advances in peptide-based subunit nanovaccines

(2014) Mariusz Skwarczynski et al.   Nanomedicine

Proof of principle for epitope-focused vaccine design

(2014) Bruno E. Correia et al.   NATURE

A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats

(2013) Tobias Kamphuis et al.   Influenza and Other Respiratory Viruses

Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation

(2013) R. Garg et al.   JOURNAL OF GENERAL VIROLOGY

Determining the Breadth of the Respiratory Syncytial Virus-Specific T Cell Response

(2013) D. S. McDermott et al.   JOURNAL OF VIROLOGY

Evaluation of an Intranasal Virosomal Vaccine against Respiratory Syncytial Virus in Mice: Effect of TLR2 and NOD2 Ligands on Induction of Systemic and Mucosal Immune Responses

(2013) Muhammad Shafique et al.   PLoS One

A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles

(2013) Alan Rigter et al.   PLoS One

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

(2013) J. S. McLellan et al.   SCIENCE

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

(2013) J. S. McLellan et al.   SCIENCE

Strategic priorities for respiratory syncytial virus (RSV) vaccine development

(2013) L.J. Anderson et al.   VACCINE

A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology

(2013) Jorge C.G. Blanco et al.   VACCINE

Neonatal Immunization with Respiratory Syncytial Virus Glycoprotein Fragment Induces Protective Immunity in the Presence of Maternal Antibodies in Mice

(2013) Youran Noh et al.   VIRAL IMMUNOLOGY

Long-Term and Memory Immune Responses in Mice against Newcastle Disease Virus-Like Particles Containing Respiratory Syncytial Virus Glycoprotein Ectodomains

(2012) M. R. Schmidt et al.   JOURNAL OF VIROLOGY

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Rafael Lozano et al.   LANCET

Influenza and respiratory syncytial virus (RSV) vaccines for infants: Safety, immunogenicity, and efficacy

(2012) Judy A. Beeler et al.   MICROBIAL PATHOGENESIS

Dual Role of Respiratory Syncytial Virus Glycoprotein Fragment as a Mucosal Immunogen and Chemotactic Adjuvant

(2012) Sol Kim et al.   PLoS One

Nucleoprotein Nanostructures Combined with Adjuvants Adapted to the Neonatal Immune Context: A Candidate Mucosal RSV Vaccine

(2012) Aude Remot et al.   PLoS One

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development

(2012) Natasha Kushnir et al.   VACCINE

Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles

(2012) S. Garlapati et al.   VACCINE

Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine

(2012) Gregory M. Glenn et al.   VACCINE

Pattern recognition receptors for respiratory syncytial virus infection and design of vaccines

(2012) Ruihong Zeng et al.   VIRUS RESEARCH

Peptide-Based Subunit Nanovaccines

(2012) Mariusz Skwarczynski et al.   Current Drug Delivery

Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA

(2011) Dong-Bum Kim et al.   BMB Reports

Particulate vaccines: on the quest for optimal delivery and immune response

(2011) Marie-Luce De Temmerman et al.   DRUG DISCOVERY TODAY

Viruslike Particle Vaccine Induces Protection Against Respiratory Syncytial Virus Infection in Mice

(2011) Fu-Shi Quan et al.   JOURNAL OF INFECTIOUS DISEASES

Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus

(2011) Jason S. McLellan et al.   JOURNAL OF MOLECULAR BIOLOGY

Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines

(2011) Stacey L. Demento et al.   TRENDS IN BIOTECHNOLOGY

Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists

(2010) Matthew Black et al.   Expert Review of Vaccines

Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

(2010) K. Huang et al.   JOURNAL OF VIROLOGY

Assembly and Immunological Properties of Newcastle Disease Virus-Like Particles Containing the Respiratory Syncytial Virus F and G Proteins

(2010) L. W. McGinnes et al.   JOURNAL OF VIROLOGY

Expression and characterization of a multivalent human respiratory syncytial virus protein

(2010) P. Subbarayan et al.   MOLECULAR BIOLOGY

Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation

(2010) Toon Stegmann et al.   VACCINE

TLR-based immune adjuvants

(2010) Folkert Steinhagen et al.   VACCINE

Respiratory Syncytial Virus Vaccine Development

(2009) Yoshihiko Murata   CLINICS IN LABORATORY MEDICINE

Newcastle Disease Virus-Like Particles Containing Respiratory Syncytial Virus G Protein Induced Protection in BALB/c Mice, with No Evidence of Immunopathology

(2009) M. R. Murawski et al.   JOURNAL OF VIROLOGY

Respiratory Syncytial Virus Grown in Vero Cells Contains a Truncated Attachment Protein That Alters Its Infectivity and Dependence on Glycosaminoglycans

(2009) S. Kwilas et al.   JOURNAL OF VIROLOGY

Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice

(2009) W. Zhang et al.   JOURNAL OF VIROLOGY

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults ≥65 years of age

(2009) Joanne M. Langley et al.   VACCINE

Nanoparticle vaccines against respiratory viruses

(2009) Brian M. Adair   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-Like protein in mice

(2008) Ruihong Zeng et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The coming of age of virus-like particle vaccines

(2008) Gary T. Jennings et al.   BIOLOGICAL CHEMISTRY

Comparison of the Safety and Immunogenicity of 2 Respiratory Syncytial Virus (RSV) Vaccines— Nonadjuvanted Vaccine or Vaccine Adjuvanted with Alum—Given Concomitantly with Influenza Vaccine to High‐Risk Elderly Individuals

(2008) Ann R. Falsey et al.   JOURNAL OF INFECTIOUS DISEASES

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

(2008) Maria Florencia Delgado et al.   NATURE MEDICINE

Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain

(2008) Siok Wan Gan et al.   PROTEIN SCIENCE